The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137
A Landscape of Pharmacogenomic Interactions in Cancer
Iorio, F., Knijnenburg, T. A., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., Aben, N., Gonçalves, E., Barthorpe, S., Lightfoot, H., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.017 · Cited by 2,090
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
Edwards, B. K., Noone, A., Mariotto, A. B., Simard, E. P., Boscoe, F. P., Henley, S. J., Jemal, A., Cho, H., Anderson, R. N., Kohler, B. A., et al. (2014) · Cancer · doi:10.1002/cncr.28509 · Cited by 1,210
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206
Immune cell promotion of metastasis
Kitamura, T., Qian, B.-Z., & Pollard, J. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3789 · Cited by 1,158
JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
O'Shea, J. J., & Plenge, R. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.014 · Cited by 1,138
Economic burden of cancer across the European Union: a population-based cost analysis
Luengo-Fernandez, R., Leal, J., Gray, A., & Sullivan, R. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70442-x · Cited by 1,008
JAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927
Marotta, L. L. C., Almendro, V., Marusyk, A., Shipitsin, M., Schemme, J., Walker, S. R., Bloushtain-Qimron, N., Kim, J. J., Choudhury, S. A., Maruyama, R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44745 · Cited by 911
Kim, E., Kim, M., Woo, D.-H., Shin, Y., Shin, J., Chang, N., Oh, Y. T., Kim, H., Rheey, J., Nakano, I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.008 · Cited by 806
NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer
Fan, Y., Mao, R., & Yang, J. (2013) · Protein & Cell · doi:10.1007/s13238-013-2084-3 · Cited by 776
Persistently Activated Stat3 Maintains Constitutive NF-κB Activity in Tumors
Lee, H., Herrmann, A., Deng, J.-H., Kujawski, M., Niu, G., Li, Z., Forman, S., Jove, R., Pardoll, D. M., & Yu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.015 · Cited by 683
Kitamura, T., Qian, B.-Z., Soong, D., Cassetta, L., Noy, R., Sugano, G., Kato, Y., Li, J., & Pollard, J. W. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141836 · Cited by 651
The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
Thomas, S. J., Snowden, J. A., Zeidler, M. P., & Danson, S. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.233 · Cited by 637
Constitutive activation of STAT 3 in breast cancer cells: A review
Banerjee, K., & Resat, H. (2016) · International Journal of Cancer · doi:10.1002/ijc.29923 · Cited by 611
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0736-y · Cited by 590
Precision medicine for cancer with next-generation functional diagnostics
Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4015 · Cited by 570
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells
Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H.-J., & Settleman, J. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.019 · Cited by 555
JAK inhibitors in dermatology: The promise of a new drug class
Damsky, W., & King, B. A. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.12.005 · Cited by 530
JAK/STAT signaling in hematological malignancies
Vainchenker, W., & Constantinescu, S. N. (2013) · Oncogene · doi:10.1038/onc.2012.347 · Cited by 528
STAT3 Target Genes Relevant to Human Cancers
Carpenter, R., & Lo, H.-W. (2014) · Cancers · doi:10.3390/cancers6020897 · Cited by 511
Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease
Flanagan, S. E., Haapaniemi, E., Russell, M. A., Caswell, R., Allen, H. L., De Franco, E., McDonald, T. J., Rajala, H., Ramelius, A., Barton, J., et al. (2014) · Nature Genetics · doi:10.1038/ng.3040 · Cited by 508
Information networks in the mammary gland
Hennighausen, L., & Robinson, G. W. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1714 · Cited by 506
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis
Chang, Q., Bournazou, E., Sansone, P., Berishaj, M., Gao, S. P., Daly, L., Wels, J., Theilen, T., Granitto, S., Zhang, X., et al. (2013) · Neoplasia · doi:10.1593/neo.13706 · Cited by 494
STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors
Lee, H., Deng, J., Kujawski, M., Yang, C., Liu, Y., Herrmann, A., Kortylewski, M., Horne, D., Somlo, G., Forman, S., et al. (2010) · Nature Medicine · doi:10.1038/nm.2250 · Cited by 395
Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells
Küçük, C., Jiang, B., Hu, X., Zhang, W., Chan, J. K. C., Xiao, W., Lack, N., Alkan, C., Williams, J. C., Avery, K. N., et al. (2015) · Nature Communications · doi:10.1038/ncomms7025 · Cited by 393
A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms
Cojoc, M., Mäbert, K., Muders, M. H., & Dubrovska, A. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.06.004 · Cited by 393
Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B
Hennighausen, L., & Robinson, G. W. (2008) · Genes & Development · doi:10.1101/gad.1643908 · Cited by 356
Functional STAT3 deficiency compromises the generation of human T follicular helper cells
Ma, C. S., Avery, D. T., Chan, A., Batten, M., Bustamante, J., Boisson-Dupuis, S., Arkwright, P. D., Kreins, A. Y., Averbuch, D., Engelhard, D., et al. (2012) · Blood · doi:10.1182/blood-2011-11-392985 · Cited by 314
Haapaniemi, E. M., Kaustio, M., Rajala, H. L. M., van Adrichem, A. J., Kainulainen, L., Glumoff, V., Doffinger, R., Kuusanmäki, H., Heiskanen-Kosma, T., Trotta, L., et al. (2015) · Blood · doi:10.1182/blood-2014-04-570101 · Cited by 275
Guo, X., Qiu, J., Tu, T., Yang, X., Deng, L., Anders, R. A., Zhou, L., & Fu, Y.-X. (2014) · Immunity · doi:10.1016/j.immuni.2013.10.021 · Cited by 257
The Unholy Trinity: Inflammation, Cytokines, and STAT3 Shape The Cancer Microenvironment
Li, N., Grivennikov, S. I., & Karin, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.018 · Cited by 245
Britschgi, A., Andraos, R., Brinkhaus, H., Klebba, I., Romanet, V., Müller, U., Murakami, M., Radimerski, T., & Bentires-Alj, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.023 · Cited by 240
Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism
Zhao, C., Li, H., Lin, H.-J., Yang, S., Lin, J., & Liang, G. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.10.001 · Cited by 237
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
Pardanani, A., Laborde, R. R., Lasho, T. L., Finke, C., Begna, K., Al-Kali, A., Hogan, W. J., Litzow, M. R., Leontovich, A., Kowalski, M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.71 · Cited by 233
Multiple regulation pathways and pivotal biological functions of STAT3 in cancer
Yuan, J., Zhang, F., & Niu, R. (2015) · Scientific Reports · doi:10.1038/srep17663 · Cited by 230
STAT3 in the systemic inflammation of cancer cachexia
Zimmers, T. A., Fishel, M. L., & Bonetto, A. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.02.009 · Cited by 225
STAT3 in CD4+ T helper cell differentiation and inflammatory diseases
Egwuagu, C. E. (2009) · Cytokine · doi:10.1016/j.cyto.2009.07.003 · Cited by 217
The STAT3 pathway as a therapeutic target in head and neck cancer: barriers and innovations
Geiger, J. L., Grandis, J. R., & Bauman, J. E. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2015.11.022 · Cited by 193
The Role of STAT3 in Non-Small Cell Lung Cancer
Harada, D., Takigawa, N., & Kiura, K. (2014) · Cancers · doi:10.3390/cancers6020708 · Cited by 190
Targeting the tumor microenvironment: JAK-STAT3 signaling
Bournazou, E., & Bromberg, J. (2013) · JAK-STAT · doi:10.4161/jkst.23828 · Cited by 189
STAT 3 the oncogene – still eluding therapy?
Wake, M. S., & Watson, C. J. (2015) · The FEBS Journal · doi:10.1111/febs.13285 · Cited by 188
STAT proteins as novel targets for cancer therapy
Catlett-Falcone, R., Dalton, W. S., & Jove, R. (1999) · Current Opinion in Oncology · doi:10.1097/00001622-199911000-00010 · Cited by 184
Gewinner, C., Hart, G., Zachara, N., Cole, R., Beisenherz-Huss, C., & Groner, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306449200 · Cited by 178
Self-citationHasan, S., Lacout, C., Marty, C., Cuingnet, M., Solary, É., Vainchenker, W., & Villeval, J. (2013) · Blood · doi:10.1182/blood-2013-04-498956 · Cited by 174
Rani, A., & Murphy, J. J. (2016) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2015.0054 · Cited by 173
STAT3 regulated ARF expression suppresses prostate cancer metastasis
Pencik, J., Schlederer, M., Gruber, W., Unger, C., Walker, S. M., Chalaris, A., Marié, I. J., Hassler, M. R., Javaheri, T., Aksoy, O., et al. (2015) · Nature Communications · doi:10.1038/ncomms8736 · Cited by 170
Xiang, M., Birkbak, N. J., Vafaizadeh, V., Walker, S. R., Yeh, J. E., Liu, S., Kroll, Y., Boldin, M., Taganov, K., Groner, B., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2004497 · Cited by 165
Self-citationBouchekioua, A., Scourzic, L., de Wever, O., Zhang, Y., Cervera, P., Aline-Fardin, A., Mercher, T., Gaulard, P., Nyga, R., Jeziorowska, D., et al. (2014) · Leukemia · doi:10.1038/leu.2013.157 · Cited by 160
Gotthardt, D., Putz, E. M., Grundschober, E., Prchal‐Murphy, M., Straka, E., Kudweis, P., Heller, G., Bagó-Horváth, Z., Witalisz‐Siepracka, A., Cumaraswamy, A. A., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0732 · Cited by 158
The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer
Bishop, J. L., Thaper, D., & Zoubeidi, A. (2014) · Cancers · doi:10.3390/cancers6020829 · Cited by 147
Cancer Drug Resistance: A Brief Overview from a Genetic Viewpoint
Rueff, J., & Rodrigues, A. S. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3347-1_1 · Cited by 144
Poli, V., & Camporeale, A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00121 · Cited by 142
Abubaker, K., Luwor, R. B., Zhu, H., McNally, O., Quinn, M. A., Burns, C. J., Thompson, E. W., Findlay, J. K., & Ahmed, N. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-317 · Cited by 142
IL15 and T-cell Stemness in T-cell–Based Cancer Immunotherapy
Pilipow, K., Roberto, A., Roederer, M., Waldmann, T. A., Mavilio, D., & Lugli, E. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1498 · Cited by 141
Netchiporouk, E., Litvinov, I. V., Moreau, L., Gilbert, M. J., Sasseville, D., & Duvic, M. A. (2014) · Cell Cycle · doi:10.4161/15384101.2014.965061 · Cited by 136
STAT signaling in mammary gland differentiation, cell survival and tumorigenesis
Haricharan, S., & Li, Y. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.03.014 · Cited by 135
PI3K and STAT3: A New Alliance
Vogt, P. K., & Hart, J. R. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0218 · Cited by 132
Defining actionable mutations for oncology therapeutic development
Carr, T. H., McEwen, R. K., Dougherty, B. A., Johnson, J. H., Dry, J. R., Lai, Z., Ghazoui, Z. F., Laing, N. M., Hodgson, D., Cruzalegui, F. H., et al. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.35 · Cited by 130
STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo
Spitzner, M., Roesler, B., Bielfeld, C., Emons, G., Gaedcke, J., Wolff, H. A., Rave‐Fränk, M., Kramer, F., Beissbarth, T., Kitz, J., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28429 · Cited by 128
STAT3 Activation in Glioblastoma: Biochemical and Therapeutic Implications
Kim, J., Patel, M. A., Ruzevick, J., Jackson, C. M., & Lim, M. K. (2014) · Cancers · doi:10.3390/cancers6010376 · Cited by 128
Directly targeting transcriptional dysregulation in cancer
Gonda, T. J., & Ramsay, R. G. (2015) · Nature reviews. Cancer · doi:10.1038/nrc4018 · Cited by 124
Bandapalli, O. R., Schuessele, S., Kunz, J. B., Rausch, T., Stütz, A. M., Tal, N., Geron, I., Gershman, N., Izraeli, S., Eilers, J., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.104992 · Cited by 123
Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer
Walker, S. R., Xiang, M. H., & Frank, D. A. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.03.010 · Cited by 117
Evolution of Cytokine Receptor Signaling
Liongue, C., Sertori, R., & Ward, A. C. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600372 · Cited by 117
NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age
Gray, G. K., McFarland, B. C., Nozell, S. E., & Benveniste, E. N. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.964211 · Cited by 109
Bottos, A., Gotthardt, D., Gill, J. W., Gattelli, A., Frei, A., Tzankov, A., Sexl, V., Wodnar‐Filipowicz, A., & Hynes, N. E. (2016) · Nature Communications · doi:10.1038/ncomms12258 · Cited by 109
The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders
Furumoto, Y., & Gadina, M. (2013) · BioDrugs · doi:10.1007/s40259-013-0040-7 · Cited by 107
Mishra, A., Perle, K. L., Kwiatkowski, S., Sullivan, L. A., Sams, G. H., Johns, J., Curphey, D. P., Wen, J., McConnell, K. K., Qi, J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1297 · Cited by 106
Gong, A., Wei, P. Y., Zhang, S., Yao, J., Yuan, Y., Zhou, A., Lang, F. F., Heimberger, A. B., Rao, G., & Huang, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2800 · Cited by 102
Keohane, C., Kordasti, S. Y., Seidl, T., Abellan, P. P., Thomas, N. S. B., Harrison, C. N., McLornan, D. P., & Mufti, G. J. (2015) · British Journal of Haematology · doi:10.1111/bjh.13519 · Cited by 102
Salmonella protein AvrA activates the STAT3 signaling pathway in colon cancer
Lu, R., Wu, S., Zhang, Y.-G., Xia, Y., Zhou, Z., Kato, I., Dong, H., Bissonnette, M., & Sun, J. (2016) · Neoplasia · doi:10.1016/j.neo.2016.04.001 · Cited by 99
Anxa2 binds to STAT3 and promotes epithelial to mesenchymal transition in breast cancer cells
Wang, T., Yuan, J., Zhang, J., Tian, R., Ji, W., Zhou, Y., Yang, Y., Song, W., Zhang, F., & Niu, R. (2015) · Oncotarget · doi:10.18632/oncotarget.5199 · Cited by 97
Tu, B., Zhu, J., Liu, S., Wang, L., Fan, Q., Hao, Y., Fan, C., & Tang, T.-T. (2016) · Oncotarget · doi:10.18632/oncotarget.10219 · Cited by 95
Wen, W. X., Wu, J., Liu, L., Tian, Y., Buettner, R., Hsieh, M.-Y., Horne, D. A., Dellinger, T. H., Han, E. S., Jove, R., et al. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0366-5 · Cited by 95
Immunological Consequences of JAK Inhibition: Friend or Foe?
McLornan, D. P., Khan, A. A., & Harrison, C. N. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0284-z · Cited by 93
STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy
Spitzner, M., Ebner, R., Wolff, H. A., Ghadimi, Β. M., Wienands, J., & Grade, M. (2014) · Cancers · doi:10.3390/cancers6041986 · Cited by 93
Zhang, M., Griner, L. A. M., Ju, W., Duveau, D. Y., Guha, R., Petrus, M. N., Wen, B., Maeda, M., Shinn, P., Ferrer, M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516208112 · Cited by 93
Desrivières, S., Kunz, C., Barash, I., Vafaizadeh, V., Borghouts, C., & Groner, B. (2006) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-006-9014-4 · Cited by 91
Self-citationWen, W. X., Liang, W. P., Wu, J., Kowolik, C. M., Buettner, R., Scuto, A., Hsieh, M.-Y., Hong, H., Brown, C. E., Forman, S. J., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0077 · Cited by 88
Vafaizadeh, V., Klemmt, P. A. B., Brendel, C., Riecken, K., Doebele, C., Britt, K. L., Grez, M., Fehse, B., Desrivières, S., & Groner, B. (2010) · Stem Cells · doi:10.1002/stem.407 · Cited by 83
Self-citationPhesse, T. J., Büchert, M., Stuart, E. C., Flanagan, D. J., Faux, M. C., Afshar‐Sterle, S., Walker, F., Zhang, H., Nowell, C. J., Jorissen, R. N., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2005411 · Cited by 77
STAT3 silencing inhibits glioma single cell infiltration and tumor growth
Priester, M., Copanaki, E., Vafaizadeh, V., Hensel, S., Bernreuther, C., Glatzel, M., Seifert, V., Groner, B., Kögel, D., & Weissenberger, J. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not025 · Cited by 76
Self-citationCombining targeted therapy with immunotherapy. Can 1+1 equal more than 2?
Robert, L., Ribas, A., & Hu‐Lieskovan, S. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.01.001 · Cited by 73
The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
Tan, F. H., Putoczki, T. L., Stylli, S. S., & Luwor, R. B. (2014) · Current Drug Targets · doi:10.2174/1389450115666141120104146 · Cited by 71
Sai, K., Wang, S., Balasubramaniyan, V., Conrad, C. A., Lang, F. F., Aldape, K., Szymański, S., Fokt, I., Dasgupta, A., Madden, T. L., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0786-z · Cited by 69
Freund, P., Kerenyi, M. A., Hager, M., Wagner, T., Wingelhofer, B., Pham, H. T. T., Elabd, M., Han, X., Valent, P., Gouilleux, F., et al. (2017) · Leukemia · doi:10.1038/leu.2017.4 · Cited by 69
Self-citationBibi, S., Arslanhan, M. D., Langenfeld, F., Jeanningros, S., Cerny‐Reiterer, S., Hadzijusufovic, E., Tchertanov, L., Moriggl, R., Valent, P., & Arock, M. (2014) · Haematologica · doi:10.3324/haematol.2013.098442 · Cited by 68
The Stat3 paradox: A killer and an oncogene
Resemann, H. K., Watson, C. J., & Lloyd‐Lewis, B. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.06.029 · Cited by 68
Schmidt, J. W., Wehde, B. L., Sakamoto, K., Triplett, A. A., Anderson, S. M., Tsichlis, P. N., Leone, G. W., & Wagner, K. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01220-13 · Cited by 67
JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors
Gao, S. P., Chang, Q., Mao, N., Daly, L., VOGEL, R. M., Chan, T., Liu, S. H., Bournazou, E., Schori, E., Zhang, H., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aac8460 · Cited by 66
Epithelial gp130/Stat3 functions: An intestinal signaling node in health and disease
Ernst, M., Thiem, S., Nguyen, P. M., Eissmann, M. F., & Putoczki, T. L. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2013.12.006 · Cited by 63
STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics
Zulkifli, A., Tan, F. H., Putoczki, T. L., Stylli, S. S., & Luwor, R. B. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.010 · Cited by 59
Couronné, L., Scourzic, L., Pilati, C., Della-Valle, V., Duffourd, Y., Solary, É., Vainchenker, W., Merlio, J., Beylot-Barry, M., Damm, F., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.085068 · Cited by 58
Yu, C., Dambuza, I. M., Lee, Y., Frank, G. M., & Egwuagu, C. E. (2013) · Mediators of Inflammation · doi:10.1155/2013/359674 · Cited by 57
Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia
Berger, A., Sexl, V., Valent, P., & Moriggl, R. (2014) · Oncotarget · doi:10.18632/oncotarget.2465 · Cited by 52
Friedman, A. A., Amzallag, A., Pruteanu-Malinici, I., Baniya, S., Cooper, Z. A., Piris, A., Hargreaves, L., Igras, V., Frederick, D. T., Lawrence, D. P., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140310 · Cited by 50
Bourgeais, J., Ishac, N., Medrzycki, M., Brachet‐Botineau, M., Desbourdes, L. M., Gouilleux‐Gruart, V., Pecnard, E., Rouleux‐Bonnin, F., Gyan, E., Domenech, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11480 · Cited by 48
Borghouts, C., Kunz, C., Delis, N., & Groner, B. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0245 · Cited by 46
Self-citationZhao, C., Wang, W., Yu, W., Jou, D., Wang, Y., Ma, H., Xiao, H., Qin, H., Zhang, C., Lü, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7338 · Cited by 45
Scaglia, P. A., Martínez, A. S., Feigerlová, E., Bezrodnik, L., Gaillard, M. I., Giovanni, D. D., Ballerini, M. G., Jasper, H., Heinrich, J. J., Peng, F., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2554 · Cited by 44
The Role of STAT3 in Thyroid Cancer
Sosonkina, N., Starenki, D., & Park, J. (2014) · Cancers · doi:10.3390/cancers6010526 · Cited by 44
Zheng, Y., Wang, Z., Deng, L., Zhang, G., Yuan, X., Huang, L., Xu, W., & Shen, L. (2015) · Clinical Immunology · doi:10.1016/j.clim.2014.12.012 · Cited by 44
Mirtti, T. K., Leiby, B. E., Abdulghani, J., Aaltonen, E., Pavela, M., Mamtani, A., Alanen, K. A., Egevad, L., Granfors, T., Josefsson, A., et al. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.06.001 · Cited by 44
Dynamic Trafficking of STAT5 Depends on an Unconventional Nuclear Localization Signal
Shin, H. Y., & Reich, N. C. (2013) · Journal of Cell Science · doi:10.1242/jcs.123042 · Cited by 43
Fox, J. L., & Storey, A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1340 · Cited by 43
Yang, C. M., Chiba, T., Brill, B., Delis, N., von Manstein, V., Vafaizadeh, V., Oellerich, T., & Groner, B. (2015) · International Journal of Cancer · doi:10.1002/ijc.29606 · Cited by 40
Self-citationPrecision Medicine in Breast Cancer: Genes, Genomes, and the Future of Genomically Driven Treatments
Stover, D. G., & Wagle, N. (2015) · Current Oncology Reports · doi:10.1007/s11912-015-0438-0 · Cited by 39
Lee, M. M. K., Chui, R. K. S., Tam, I. Y. S., Lau, H. Y. A., & Wong, Y. H. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103359 · Cited by 38
JAK Mutations as Escape Mechanisms to Anti–PD-1 Therapy
Marabelle, A., Aspeslagh, S., Postel-Vinay, S. C., & Soria, J. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1439 · Cited by 37
Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade
Curran, S. A., Shyer, J. A., Angelo, E. T. S., Talbot, L. R., Sharma, S., Chung, D. J., Heller, G., Hsu, K. C., Betts, B. C., & Young, J. W. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0233 · Cited by 35
Assi, H. H., Paran, C., VanderVeen, N. T., Savakus, J. C., Doherty, R., Petruzzella, E., Hoeschele, J. D., Appelman, H. D., Raptis, L. H., Mikkelsen, T., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.214619 · Cited by 34
Borghouts, C., Tittmann, H., Delis, N., Kirchenbauer, M., Brill, B., & Groner, B. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0417 · Cited by 34
Self-citationJanus Kinases: An Ideal Target for the Treatment of Autoimmune Diseases
Gadina, M. (2013) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1038/jidsymp.2013.29 · Cited by 33
Janus Kinase 1 Is Essential for Inflammatory Cytokine Signaling and Mammary Gland Remodeling
Sakamoto, K., Wehde, B. L., Yoo, K. H., Kim, T., Rajbhandari, N., Shin, H. Y., Triplett, A. A., Rädler, P. D., Schuler, F., Villunger, A., et al. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00999-15 · Cited by 33
STAT3 Activity and Function in Cancer: Modulation by STAT5 and miR-146b
Walker, S. R., Xiang, M. H., & Frank, D. A. (2014) · Cancers · doi:10.3390/cancers6020958 · Cited by 27
Weber, A., Borghouts, C., Brendel, C., Moriggl, R., Delis, N., Brill, B., Vafaizadeh, V., & Groner, B. (2013) · Pharmaceuticals · doi:10.3390/ph6080960 · Cited by 26
Self-citationGroner, B., Weber, A., & Mack, L. (2012) · Bioengineered · doi:10.4161/bioe.21272 · Cited by 25
Self-citationGenetic Interactions of STAT3 and Anticancer Drug Development
Fang, B. (2014) · Cancers · doi:10.3390/cancers6010494 · Cited by 25
Cancer Stem Cells Activate STAT3 the EZ Way
Fouse, S. D., & Costello, J. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.016 · Cited by 24
Determinants of the extent and duration of STAT3 signaling
Groner, B. (2012) · JAK-STAT · doi:10.4161/jkst.21469 · Cited by 24
Self-citationWeber, A., Borghouts, C., Brendel, C., Moriggl, R., Delis, N., Brill, B., Vafaizadeh, V., & Groner, B. (2015) · Cancers · doi:10.3390/cancers7010503 · Cited by 22
Self-citationBorghouts, C., Delis, N., Brill, B., Weiß, A., Mack, L., Lucks, P., & Groner, B. (2012) · JAK-STAT · doi:10.4161/jkst.18947 · Cited by 20
Self-citationLoss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance
Putz, E. M., Hoelzl, M. A., Baeck, J., Bagó-Horváth, Z., Schuster, C., Reichholf, B., Kern, D., Aberger, F., Sexl, V., & Hoelbl‐Kovacic, A. (2014) · Cancers · doi:10.3390/cancers6010193 · Cited by 16
von Manstein, V., & Groner, B. (2016) · MedChemComm · doi:10.1039/c6md00463f · Cited by 16
Self-citationAssi, H. H., Espinosa, J. R., Suprise, S., Sofroniew, M. V., Doherty, R. E., Zamler, D. B., Lowenstein, P. R., & Castro, M. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096318 · Cited by 13
Keohane, C., McLornan, D. P., Sanchez, K., Connor, C., Radia, D. H., & Harrison, C. N. (2015) · Haematologica · doi:10.3324/haematol.2015.128918 · Cited by 13
Groner, B., & Hennighausen, L. G. (2012) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2012-0010 · Cited by 12
Self-citationAbubaker, K., Luwor, R. B., Escalona, R. M., McNally, O., Quinn, M. A., Thompson, E. W., Findlay, J. K., & Ahmed, N. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00075 · Cited by 9
Humar, M., Azémar, M., Maurer, M., & Groner, B. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00270 · Cited by 4
Self-citation
Cited by
Signaling pathways and targeted therapy for myocardial infarction
Zhang, Q., Wang, L., Wang, S., Cheng, H., Xu, L., Pei, G., Wang, Y., Fu, C., Jiang, Y., He, C., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00925-z · Cited by 831
JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Owen, K. L., Brockwell, N. K., & Parker, B. S. (2019) · Cancers · doi:10.3390/cancers11122002 · Cited by 714
Therapeutically exploiting STAT3 activity in cancer — using tissue repair as a road map
Huynh, J., Chand, A., Gough, D., & Ernst, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0090-8 · Cited by 504
Mesenchymal stem/stromal cells in cancer therapy
Lan, T., Luo, M., & Wei, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01208-w · Cited by 374
Bian, Z., Zhang, J., Li, M., Feng, Y., Wang, X., Zhang, J., Yao, S., Jin, G., Du, J., Han, W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2967 · Cited by 305
Metadata
- Authors
- Groner, B., & von Manstein, V.
- Venue
- Molecular and Cellular Endocrinology
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 451
- Pages
- 1-14
- ISSN
- 0303-7207 (ISSN-L)
- OpenAlex
- W2618558825
- Cited by
- 306
- References
- 135
- FWCI
- 12.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.